Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 6—June 2020
Research Letter

Donor-Derived Transmission of Cryptococcus gattii sensu lato in Kidney Transplant Recipients

Author affiliations: Hospital do Rim, São Paulo, Brazil (D. W.C.L. Santos, M.P. Cristelli, L.A. Viana, H. Tedesco-Silva, J.O. Medina-Pestana); Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo (D.W.C.L. Santos, A.L. Colombo); Canisius Wilhelmina Hospital, Nijmegen, the Netherlands (F. Hagen, J.F. Meis); Westerdijk Fungal Biodiversity Institute, Utrecht, The Netherlands (F. Hagen); Centre of Expertise in Mycology Radboudumc/CWZ, Nijmegen, the Netherlands (J.F. Meis); Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo (F.D.C. Bernardi)

Cite This Article

Abstract

We describe cases of donor-derived transmission of Cryptococcus deuterogattii in 2 kidney transplant recipients in Brazil and published information on other cases. Prompt reduction of immunosuppression and initiation of antifungal therapy was required to successfully control the fungal infections and preserve engraftment.

After antiretroviral therapy for HIV patients was introduced, solid organ transplant recipients became one of the major risk groups for developing cryptococcosis, possibly transmitted from donors (1,2). We describe 2 cases of donor-derived transmission of Cryptococcus deuterogattii in Brazil. The donor in both of these cases was a 43-year-old man with an antemortem history of an unspecified brain tumor who had been declared brain dead after respiratory arrest.

Case-patient 1 was a 51-year-old man who received a kidney from the donor. Physicians initiated induction therapy with antithymocyte globulin and maintenance therapy with tacrolimus, prednisone, and azathioprine. On day 7 after the procedure, doctors performed a kidney biopsy after the patient experienced delayed graft function. Histopathology of the graft showed organisms consistent with Cryptococcus yeast cells, suggesting fungal pyelonephritis. The patient had no respiratory or neurologic complaints. Results from his laboratory tests showed 7,000 leukocytes/mm3, 201,000 platelets/μL, serum creatinine 13.29 mg/dL, and serum urea 132 mg/dL. Brain and thorax radiographs revealed no abnormalities. Results of a lumbar puncture showed an opening pressure of 18 cm H2O, 2 leukocytes/mm3, protein 63 mg/dL, and glucose 77 mg/dL; a Cryptococcus antigen latex (CrAg-latex) agglutination test result was positive (titer 1:8). Blood and urine cultures indicated Cryptococcus species, and the serum CrAg-latex agglutination test result was positive (titer 1:1,024).

After the diagnosis of cryptococcosis in the first patient, a 59-year-old woman (case-patient 2) who had received a kidney from the same donor was contacted for evaluation. Physicians had initiated induction therapy with antithymocyte globulin and maintenance therapy with tacrolimus, prednisone, and mycophenolic acid. She was discharged on day 8 after the procedure and was asymptomatic when recalled on day 10. Clinicians performed blood and urine cultures, radiographs of the chest and the brain, and a lumbar puncture. The radiograph revealed no abnormalities. Results of lumbar puncture showed opening pressure of 15 cm H2O, 3 leukocytes/mm3, protein 35 mg/dL, and glucose 174 mg/dL. Results of India ink and CrAg-latex agglutination tests were positive (titer: 1:64). Blood cultures and a urine sample indicated Cryptococcus species. No fungal growth was detected in a cerebrospinal fluid sample. The serum CrAg-latex agglutination was positive (titer 1:1,024).

A revised histology of the brain biopsy of the donor showed yeasts of Cryptococcus species that had not been detected previously. Results of a CrAg-latex agglutination test performed on a stored serum sample from the donor was positive (titer: 1:1,024). To rule out infection by Cryptococcus species in the organ recipients prior to the transplantations, CrAg-latex agglutination tests were performed on stored pretransplant serum samples from both recipients; results for both were negative.

Both patients were treated with amphotericin B lipid complex (5 mg/kg 1×/d for 21 d) in combination with 5-fluorocytosine (25 mg/kg 4×/d for 14 d); dosages of immunosuppressive drugs were lowered. Therapy was switched to intravenous fluconazole (400 mg/d) after results of blood and urine cultures became negative. After clinical and microbiological remission of the infection, dosage was adjusted on the basis of renal function to 300 mg/d of oral fluconazole and was maintained for 2 years. Three years after stopping all antifungal therapy, no relapse of cryptococcosis was documented.

Figure

Thumbnail of Phylogenetic maximum-likelihood analysis of 6 Cryptococcus deuterogattii isolates from 2 kidney transplant recipients in Brazil (blue), the organ donor (red), and cases from the literature (Appendix, https://wwwnc.cdc.gov/EID/article/26/6/19-1765-App1.pdf), along with reference isolates. Isolates from the 2 transplant recipients came from blood and urine; the genetic material from the donor came from a formalin-fixed paraffin-embedded brain tissue block. The GenBank accession number

Figure. Phylogenetic maximum-likelihood analysis of 6 Cryptococcus deuterogattii isolates from 2 kidney transplant recipients in Brazil (blue), the organ donor (red), and cases from the literature (Appendix, https://wwwnc.cdc.gov/EID/article/26/6/19-1765-App1.pdf), along with reference...

All 6 isolates from the recipients were characterized at a reference laboratory at Universidade Federal de São Paulo (São Paulo, Brazil) and sent to Canisius-Wilhelmina Hospital (Nijmegen, The Netherlands). We performed AFLP (amplified fragment length polymorphism) fingerprinting and multilocus sequencing typing, which showed that all isolates were C. deuterogattii genotype AFLP6/VGII. The revision of slides from formalin-fixed paraffin-embedded tissue blocks from donor brain biopsies showed Cryptococcus yeasts. We performed fungal DNA extraction and amplified parts of CAP59, GPD1, IGS1, LAC1, PLB1, SOD1, and URA5 loci (2). Phylogenetic analysis showed genetic similarity between the C. deuterogattii isolates from the kidney recipients and those from the donor’s brain (Figure).

We searched the literature for other cases of fungal infections from solid organ donors in transplant recipients and found 12 additional cases of presumed or confirmed donor-derived cryptococcosis (Appendix). Molecular identification was provided in only 6 out of 14 graft recipients (310). On the basis of the 2 cases we describe and data from the literature review, we suggest the following procedures for effective clinical management: performing blood and urine cultures, radiograph of the lungs and brain, and lumbar puncture to rule out dissemination; reducing immunosuppression to control infection; promptly initiating induction combination therapy with an amphotericin B lipid complex and 5-fluorocytosine; preserving the infected engraftment, if possible, in the absence of large fungal masses and abscesses; and extending the length of antifungal therapy when fungal elements persist in tissues.

In conclusion, we found that C. deuterogattii may be transmitted by infected allografts, representing a medical concern in countries to which C. gattii species complex is endemic. Cryptococcosis incidence might be reduced by excluding organ donor candidates with a history of neurologic disease without a clear definition of its etiology. Ensuring that clinicians are trained to recognize and treat this fungal infection would likely further reduce transmission from donors.

Dr. Santos is a PhD student at the Federal University of São Paulo (UNIFESP), an infectious diseases specialist at the Kidney Hospital, São Paulo, and a clinical researcher at the Special Mycology Laboratory, Division of Infectious Diseases, Escola Paulista de Medicina, UNIFESP. His main research is on melanized fungal infections (phaeohyphomycosis and chromoblastomycosis) and infections in solid organ transplant patients.

Top

Acknowledgments

We are grateful to the team of infectious diseases and nephrologists responsible for the medical assistance to solid organ transplant recipients at the Hospital do Rim (UNIFESP).

There is no funding source for the research in question. There is no organization with a financial interest in the subject matter. The authors report no conflicts of interest for this research and are responsible for the content and writing of this paper. All the authors reviewed, approved, and contributed to the final version of the manuscript.

Top

References

  1. Baddley  JW, Forrest  GN; AST Infectious Diseases Community of Practice. Cryptococcosis in solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33:e13543. DOIPubMedGoogle Scholar
  2. Hagen  F, Khayhan  K, Theelen  B, Kolecka  A, Polacheck  I, Sionov  E, et al. Recognition of seven species in the Cryptococcus gattii/Cryptococcus neoformans species complex. Fungal Genet Biol. 2015;78:1648. DOIPubMedGoogle Scholar
  3. Ooi  BS, Chen  BT, Lim  CH, Khoo  OT, Chan  DT. Survival of a patient transplanted with a kidney infected with Cryptococcus neoformans. Transplantation. 1971;11:4289. DOIPubMedGoogle Scholar
  4. Beyt  BE Jr, Waltman  SR. Cryptococcal endophthalmitis after corneal transplantation. N Engl J Med. 1978;298:8256. DOIPubMedGoogle Scholar
  5. Kanj  SS, Welty-Wolf  K, Madden  J, Tapson  V, Baz  MA, Davis  RD, et al. Fungal infections in lung and heart-lung transplant recipients. Report of 9 cases and review of the literature. Medicine (Baltimore). 1996;75:14256. DOIPubMedGoogle Scholar
  6. de Castro  LE, Sarraf  OA, Lally  JM, Sandoval  HP, Solomon  KD, Vroman  DT. Cryptococcus albidus keratitis after corneal transplantation. Cornea. 2005;24:8823. DOIPubMedGoogle Scholar
  7. Baddley  JW, Schain  DC, Gupte  AA, Lodhi  SA, Kayler  LK, Frade  JP, et al. Transmission of Cryptococcus neoformans by organ transplantation. Clin Infect Dis. 2011;52:e948. DOIPubMedGoogle Scholar
  8. MacEwen  CR, Ryan  A, Winearls  CG. Donor transmission of Cryptococcus neoformans presenting late after renal transplantation. Clin Kidney J. 2013;6:2247. DOIPubMedGoogle Scholar
  9. Chang  CM, Tsai  CC, Tseng  CE, Tseng  CW, Tseng  KC, Lin  CW, et al. Donor-derived Cryptococcus infection in liver transplant: case report and literature review. Exp Clin Transplant. 2014;12:747. DOIPubMedGoogle Scholar
  10. Camargo  JF, Simkins  J, Schain  DC, Gonzalez  AA, Alcaide  ML, Anjan  S, et al. A cluster of donor-derived Cryptococcus neoformans infection affecting lung, liver, and kidney transplant recipients: Case report and review of literature. Transpl Infect Dis. 2018;20:e12836. DOIPubMedGoogle Scholar

Top

Figure

Top

Cite This Article

DOI: 10.3201/eid2606.191765

Original Publication Date: May 06, 2020

Table of Contents – Volume 26, Number 6—June 2020

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Arnaldo L. Colombo, Laboratório Especial de Micologia, Disciplina de Infectologia, Universidade Federal de São Paulo, São Paulo-SP. Rua Botucatu, 740. CEP 04023-062, São Paulo, Brazil

Send To

10000 character(s) remaining.

Top

Page created: May 19, 2020
Page updated: May 19, 2020
Page reviewed: May 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external